NCT04712396 - A Study to Assess How Itraconazole Affects the Uptake and Elimination of Capivasertib in the Body | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

March 25, 2021

Study Completion Date

March 25, 2021

Conditions

Healthy Volunteers (Intended Indication: Metastatic Patients With Triple Negative or HR+ Breast Cancer, or Hormone Sensitive Prostate Cancer)

Interventions

DRUG

Capivasertib

Subects will be administered single doses of capiversatib on Day 1 and Day 6.

DRUG

Itraconazole

Subjects will be administered itraconazole twice daily on Day 3, followed by once daily doses in the morning for 4 days.

Trial Locations (1)

Research Site, Berlin